Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415332 | 0.90 | — | — | |
| SCHEMBL13391543 | 0.83 | — | — | |
| SCHEMBL19798957 | 0.81 | BCHE (0.35) | — | |
| SCHEMBL12050687 | 0.81 | SMN1; SMN2 (0.33) | MAPTSMN1; SMN2TP53 | |
| SCHEMBL2535091 | 0.79 | SMN1; SMN2 (0.37) | MAPTSMN1; SMN2TP53 | |
| SCHEMBL31623264 | 0.78 | HSD11B1 (0.33) | — | |
| SCHEMBL428708 | 0.78 | — | — | |
| SCHEMBL17464288 | 0.77 | — | — | |
| SCHEMBL2213404 | 0.76 | MAPT (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL190770 | 0.76 | KDM4E (0.38) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | MAPT 3683/4885SMN1; SMN2 4316/4885TP53 112/4885 |
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | ADRM1, CYP2E1, OPRD1 | MAPT 3033/4885SMN1; SMN2 1908/4885TP53 4244/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | MAPT 3731/4885SMN1; SMN2 3973/4885TP53 135/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | MAPT 3519/4885SMN1; SMN2 3842/4885TP53 120/4885 |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | CYP2E1, CYP1A1, ADRM1 | MAPT 3056/4885SMN1; SMN2 2417/4885TP53 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.